Effect of cyclosporine a and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation
Authors:
- 11 October 2019
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (5) , 614-619
Abstract
1. Voriconazole is known to display highly variable pharmacokinetics affecting treatment efficacy and safety. This study aimed to identify the factors causing the variation of voriconazole concentration in patients with allogeneic hematopoietic stem cell transplantation. 2. The data of patients was collected, including clinical characteristics and voriconazole concentrations. A total of 5 single nucleotide polymorphisms of 3 candidate genes (CYP2C19, ABCC2, ABCG2) related to voriconazole metabolism were genotyped by MassArray method. The correlation between polymorphisms and voriconazole concentration was analyzed. 3. A total of 244 voriconazole concentrations of 43 patients were included in this study. The voriconazole concentration was significantly correlated with patients' total bile acid (P =0.001) and cyclosporin A (P < 0.001). The median concentration of the CYP2C19 normal metabolizers was remarkably lower than poor metabolizers (0.86 vs 2.27 μg/mL). The median concentration of ABCC2 rs2273697 GG genotype carriers was significantly higher than that of GA genotype carriers (P = 0.026). 4. The variability of voriconazole concentration is partially explained by total bile acid, metabolic types of CYP2C19. The voriconazole concentration of CYP2C19 normal metabolizers is likely to be lower than 1.0 μg/mL and thus at risk of infection due to inadequate treatment.Keywords
This publication has 27 references indexed in Scilit:
- Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscessInternational Journal of STD & AIDS, 2014
- Voriconazole pharmacokinetics and exposure–response relationships: Assessing the links between exposure, efficacy and toxicityInternational Journal of Antimicrobial Agents, 2014
- Differential Effects of Membrane Cholesterol Content on the Transport Activity of Multidrug Resistance–Associated Protein 2 (ABCC2) and of the Bile Salt Export Pump (ABCB11)Molecular Pharmacology, 2014
- Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography–tandem mass spectrometryJournal of Chromatography B, 2013
- Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug MonitoringAntimicrobial Agents and Chemotherapy, 2012
- Variable magnitude of drug interaction between oral voriconazole and cyclosporineAin recipients of allogeneic hematopoietic stem cell transplantationClinical Transplantation, 2012
- Pharmacogenomics of the Triazole Antifungal Agent VoriconazolePharmacogenomics, 2011
- Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphismEuropean Journal of Clinical Pharmacology, 2010
- Accelerated Metabolism of Voriconazole and Its Partial Reversal by CimetidineAntimicrobial Agents and Chemotherapy, 2009
- Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipientsBone Marrow Transplantation, 2005